PREVENTION AND TREATMENT OF A PULMONARY BACTERIAL INFECTION OR A SYMPTOMATIC PULMONARY EXPOSURE TO ENDOTOXIN BY INHALATION OF ANTIENDOTOXINIC PHARMACOS.

摘要

Use of an antiendotoxin compound for the preparation of a pharmaceutical composition intended for the prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin, in a patient, wherein said pharmaceutical composition is administered to said patient by inhalation, in wherein said antiendotoxin compound is a Lipid A analogue, and wherein said Lipid A analogue has the formula: wherein R1 is selected from the group consisting of each one of J, K and Q, independently, it is linear or branched C1 to C15 alkyl; L is O, NH, or CH2; M is O or NH; and G is NH, O, S, SO, or SO2; R2 is linear or branched C5 to C15 alkyl; R3 is selected from the group consisting of linear or branched C5 to C18 alkyl, and in which E is NH, O, S, SO, or SO2; each of A, B and D, independently, is linear or branched C1 to C15 alkyl; R4 is selected from the group consisting of C4 to C20 linear or branched alkyl, and in which each of U and V, independently, is linear or branched C2 to C15 alkyl, and W is hydrogen or C1 to C alkyl C5 linear or branched; RA is R5 or R5-O-CH2-, R5 being selected from the group consisting of hydrogen, J¿, -J¿-OH, -J¿-OK¿, -J¿-OK¿-OH, and ¿J ¿-O-PO (OH) 2, in which each of J¿ and K¿, independently, is C1 to C5 alkyl linear or branched; R6 is selected from the group consisting of hydroxy, halogen, C1 to C5 alkoxy, and C1 to C5 acyloxy; A1 and A2, independently, are selected from the group consisting of OH, in which Z is linear or branched C1 to C10 alkyl; or pharmaceutically acceptable salts thereof.